AI

#AI #Biotechnology #Events #Life sciences #Microbiome #Webinar

Free virtual event on microbiome research 

Microbiome experts from Microba Life Sciences will discuss the next phase of discovery from the microbiome to a global audience via a series of webinars on September 15 (PST 10am-12pm | EST 1-3pm | CET 7pm).  Professor Gene Tyson, Associate Professor Lutz Krause and Dr Alena Pribyl will discuss how advancements in metagenomic… Read More

#News

#AI #Drug development #Immuno-oncology #Machine learning #Oncology

Bristol Myers Squibb develops Exscientia’s drug candidate 

Exscientia has announced that Bristol Myers Squibb has elected to in-license its immune-modulating drug candidate. Exscientia has two active collaborations with Bristol Myers Squibb, which together focus on multiple therapeutic areas, including oncology and immunology. A significant expansion of the relationship was announced earlier this year.  The in-licensed candidate targets… Read More

#Cancer Research #News

#AI #Biotechnology #Chemistry #Digital #Drug discovery #Life sciences

Digital Science launches research platform 

Digital Science has launched a new version of its Dimensions platform - Dimensions Life Sciences & Chemistry - focused on life sciences and chemistry research activities.   Dimensions L&C analyses more than 120 million scientific publications, millions of patents, grants and clinical trial documents. It applies semantic text analysis tools and ontologies, providing… Read More

#Business & Investment

#AI #AI / data analytics / healthtech / informatics #Clinical trials #Drug discovery

Insilico Medicine discovers preclinical candidate for kidney fibrosis using AI

Insilico Medicine has announced today that its AI-powered drug discovery platform has delivered a preclinical candidate for kidney fibrosis. The preclinical candidate has desirable pharmacological properties and pharmacokinetic profile and has demonstrated highly promising results in in-vitro and in-vivo preclinical studies. Insilico Medicine is working to advance this program to… Read More

#News

#AI #Biology #R&D #Therapeutics #Tumour biology

Combining AI-driven drug capabilities with CDK targets for oncology

Exscientia and GT Apeiron Therapeutics have entered an R&D collaboration. Exscientia’s AI expertise will  be used to accelerate the discovery of multiple small molecule therapeutic drug candidates designed to selectively treat aberrant cell cycle driven cancers and build a pipeline of CDK novel therapies. This collaboration follows the design of… Read More

#News

#AI #AI / data analytics / healthtech / informatics #Big pharma #Drug development #Drug discovery #GlobalData

AI and big data will continue to disrupt pharmaceutical sector, says research

The Covid-19 pandemic has given businesses opportunity to implement technology-fuelled changes to the way they operate. AI and big data/analytics have been identified by healthcare industry professionals as the top technologies that will transform pharmaceutical drug discovery and development processes, as well as marketing and sales, according to a survey… Read More

#Market Reports #News #Trending News #Trends & Analysis

#AI #AI / data analytics / healthtech / informatics #Biotherapeutics #Covid-19 #Drug design #Drug development #Therapeutics

Exscientia accelerates Covid-19 drug discovery using AI

Exscientia has received a grant from the Bill & Melinda Gates Foundation and Gates Philanthropy Partners, as part of the Covid-19 Therapeutics Accelerator initiative, to progress a new class of Covid-19 therapeutics created using its artificial intelligence (AI) drug design platform. Exscientia has demonstrated proof-of-concept by using its AI platform… Read More

#News

#AI #Augmented Chemistry #Data #Drug discovery #Pharma

Optibrium publishes study on AI applications in pharma

Optibrium has published a peer-reviewed study in Applied AI Letters, “Deep Imputation on Large-Scale Drug Discovery Data”, working alongside Takeda Pharmaceuticals’ proprietary global dataset and the Alchemite deep learning method. The study demonstrated that deep learning generates new and valuable insights on global pharma-scale, high-value and proprietary datasets. Such datasets… Read More

#News

#AI #Drug development #Drug discovery #Novel candidates #Therapeutics

Strategic collaboration could open the door to new world-class medicines

EQRx and Exscientia are collaborating to combine the AI capabilities of Exscientia to accelerate the discovery of small molecule therapeutic drug candidates and expand EQRx’s pipeline of novel therapies. This collaboration is focused on creating improvements in the traditional drug discovery and development processes by improving the probability of success… Read More

#News

#AI #AI / data analytics / healthtech / informatics #Research

AI in drug discovery will be worth $4.05 billion by 2028

The global artificial intelligence (AI) in drug discovery market size is expected to reach US$4.05 billion by 2028 according to a new study by Polaris Market Research. The report “Artificial Intelligence in Drug Discovery Market Share, Size, Trends, Industry Analysis Report, By Therapeutic Area (Oncology, Neurodegenerative Diseases, Cardiovascular Disease, Metabolic Diseases, Infectious Disease,… Read More

#News

#AI #AI / data analytics / healthtech / informatics #Drug candidates #Drug design #Drug discovery #Research

AI accelerates discovery of small molecule drug candidates

Exscientia has entered into a collaboration agreement with Bristol-Myers Squibb Company. The collaboration will use AI to accelerate the discovery of small molecule therapeutic drug candidates in multiple therapeutic areas, including oncology and immunology. This expanded collaboration builds upon Exscientia’s existing collaboration with Bristol Myers Squibb that was initiated in… Read More

#News

#AI #Biobanking #Immunology #Machine learning #Microbiology #Podcast #Precision medicine

Podcast: Precision medicine in the era of artificial intelligence

The latest episode of the free DDW podcast is out, “Precision medicine in the era of artificial intelligence”. It covers one narrated article of the same title written for DDW and read aloud by Megan Thomas. It was written by Dr Lofti Chouchane and Dr Javaid Sheikh. Dr Chouchane is… Read More

#Editor's Choice #News

#AI #Biobanking #Drug development #Drug discovery #Machine learning #Narrated podcasts

Precision medicine in the era of artificial intelligence

This is the latest episode of the free DDW podcast, “Precision medicine in the era of artificial intelligence”. It covers one narrated article of the same title written for DDW and read aloud by Megan Thomas. It was written by Dr Lofti Chouchane and Dr Javaid Sheikh, who discuss the value… Read More

#Podcasts

#AI #AI / data analytics / healthtech / informatics #Biologics / Biotechnology #Biopharmaceuticals #Drug delivery #Drug development #Drug discovery

Putting the power into drug design: the important role of AI

Valence’s co-founder and CEO, Daniel Cohen, spoke to Lu Rahman about the company’s plan to empower drug discovery scientists with AI-enabled drug design LR:  Outline of the company and its main initiatives DC: Valence is an interdisciplinary team of scientists and engineers out of Mila, the world’s largest deep learning… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#AI #AI / data analytics / healthtech / informatics #Cancer research #Drug design #Drug development #Drug discovery

First AI-designed immuno-oncology drug enters clinical trials

Exscientia, an artificial intelligence (AI)-driven pharmatech company, has announced the first AI-designed molecule for immuno-oncology to enter human clinical trials, a joint venture co-invented and developed by Exscientia and Evotec. The A2a receptor antagonist, which is in development for adult patients with advanced solid tumours, includes the application of Exscientia’s… Read More

#Cancer Research #News

#AI #AI / data analytics / healthtech / informatics #Drug discovery #Research

Charles River and Valence partner to provide AI-enabled drug design

Charles River Laboratories and Valence Discovery have teamed up to provide clients access to Valence’s artificial intelligence platform for molecular property prediction, generative chemistry, and multiparameter optimisation. Building on research done by Valence’s founding team at Mila, a deep learning research institute, the Valence platform enables the design of small… Read More

#News